Answers are grounded in this paper and cite their sources.
Despite clinical advances in CAR‐T therapy and immune checkpoint blockade, effective immunotherapy for solid tumors remains limited by restricted immune‐cell access and an immunosuppressive tumor microenvironment. Chimeric antigen receptor macrophages (CAR‐M) provide an alternative strategy by combining antigen‐directed myeloid programming with local immune remodeling. A self‐locking microneedle platform incorporating mannose‐modified nanoparticles (MNPs) enables localized in situ programming of CAR‐expressing macrophages at melanoma sites. The platform co‐delivers a tumor‐antigen‐directed CAR and a hypoxia‐responsive anti‐PD‐L1 single‐chain variable fragment (scPD‐L1). Initial studies in B16F10‐OVA tumors establish antigen‐dependent CAR activity and coordinated local immune remodeling. Therapeutic efficacy is subsequently evaluated in parental B16F10 tumors using an endogenous tyrosinase‐related protein 1 (TYRP1)‐directed CAR. MNP(TYRP1/scPD‐L1) microneedles delay tumor progression, prolong survival, and promote coordinated myeloid and CD8 + T‐cell responses, while providing lower terminal tumor burden, greater local surface CAR + tumor‐associated macrophage abundance, and reduced systemic exposure compared with dose‐matched intratumoral administration. Reciprocal depletion further shows that CAR‐programmed macrophages contribute to the antigen‐directed myeloid response, whereas CD8 + T cells are major downstream effectors required for maximal and sustained tumor control. These findings establish a localized transcutaneous strategy that coordinates antigen‐directed myeloid programming with adaptive antitumor immunity.
No takes yet. Share an insight, caveat, or question.
Hong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: